Zacks Investment Research upgraded shares of H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating) from a hold rating to a buy rating in a research note released on Monday, Zacks.com reports. The firm currently has $27.00 price objective on the stock. According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research […]
H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating) – Equities research analysts at SVB Leerink upped their FY2022 earnings per share (EPS) estimates for H. Lundbeck A/S in a report released on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the company will post earnings of $2.16 per share for the year, up […]
Zacks Investment Research upgraded shares of H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating) from a sell rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the […]
H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Friday, Zacks.com reports. According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the […]